Page 1919 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

1346 Index

LiDCOrapid™, 248 Long-term management of idiopathic Lymphocyte anergy, 555
Lidocaine, 302, 1215 pulmonary fibrosis, 520 Lymphomas, 1302
Life-sustaining therapy Long-term outcomes after critical illness,
practical aspects of withholding or 103–114 M
withdrawing, 124, 124t additional physical morbidities, Macroscopic barotrauma, 440
withholding or withdrawing, 108–109, 109f Macroscopic injury, 440
123–124, 124f barriers to construction of rehabilitative Magnesium, 965–968
Life-threatening infections of head, neck, and models after, 110 hypermagnesemia, 967–968
upper respiratory tract, 676–688 caregiver and family burden in, 113 hypomagnesemia, 966–967, 966t
clinical syndromes, 678–687 clinical phenotypes in, and spectrum of metabolism, 965–966
acute epiglottitis and disability, 107–108, 108f Magnesium sulfate, 500
laryngotracheobronchitis, critical illness-associated brain injury, Maintenance dose, 1228–1230, 1229t, 1230t
684–685, 685f 110–113 Major histocompatibility complex (MHC), 564
deep cervical fascial space infections, differential repair, 108 Malaria, 721–728
678–679, 679f, 680ft, 681t health-related quality of life, 104–105 biology of parasites, 722, 722f, 723f
lateral pharyngeal space infections, neuropsychological morbidities in critically ill traveler, 716
681–683 and, 105–106 diagnosis of, 726
pericranial infections, 685–686, 685t long-term functional disability, 105, 106f differential diagnosis of, 726
peritonsillar abscess, 680f, 683–684 myopathy, 107 epidemiology of, 722–723
submandibular space infections, neuromuscular dysfunction, 106, 106f pathophysiology, 723–726, 724t
679–681, 679f, 679t, 680f, 682f phase-specific approach to recovery acute renal impairment, 725
suppurative parotitis, 669f, 683 after, 10 cerebral malaria, 725, 725f
diagnostic considerations polyneuropathy, 106–107 circulatory changes, 726
imaging techniques, 687–688 rehabilitation framework - International cytoadherence, cytokines, and severe
microbiologic techniques, 687 Classification of Functioning, disease, 724–725
general anatomic considerations, Disability, and Health (ICF), hematological complications, 725
677, 677f, 678f 109–110 hepatic dysfunction, 725
microbial etiology and pathogenesis, sarcopenia of aging, 108 metabolic complications, 725
678, 678f treatment—early mobility and pulmonary complications, 725
therapeutic considerations, 688 rehabilitation, 113–114 treatment of severe falciparum malaria
Lightning injury, 1179 Lorazepam, 152 adjuvant therapies, 727
Linezolid, 548 https://kat.cr/user/tahir99/
antimalarial, 726–727, 726t
Lower gastrointestinal bleeding, 218–219,
Lipid-lowering agents, 298 1018–1020, 1019f of concomitant diseases, 727
Lipopeptides, 548–549, 549t Low-molecular-weight heparin supportive, 728
Liposomal doxorubicin, 896 (LMWH), 304, 328 Malignancy, acute renal failure and, 926, 926t
Lipotoxicity, 975 Low platelets syndrome, 856 Malignant hyperthermia, 561, 1061–1062, 1062t
Listeria monocytogenes, 653, 675 Low T 3 syndrome, nonthyroidal illness Malignant otitis externa, 686
Lithium, 1217–1218 (NTI), 987 Malignant spinal cord compression, 875–876
Liver thyroid physiology in brain in, 987 Mallory-Weiss tear, 1017
evaluation of, in organ Ludwig angina, 406, 679, 680 Mannitol, 1133–1134
transplantation, 1113 mortality rate for, 681 for fulminant hepatic failure, 818
injuries to, 1164–1165 therapy of, 680 for intracranial pressure, 808–809
Liver disease Lujo virus hemorrhagic fever, 739 Marburg hemorrhagic fever, 740
acute renal failure and, 927–928, 927t Lumbar puncture, 660 Massive hemoptysis, 214, 509–513, 510t, 874
effects of, 1237 Lung Allocation Score, 1091–1092 evaluation of, 511–512, 511f
Liver failure, corticosteroids in treating, 985 Lung contusion, 1158 site and etiology of bleeding, 511–513
Liver support systems, 1025 Lung disease, sickle cell disease and, 906 stabilization of, 510–511
Liver transplantation, 1025–1026, 1026f, 1031, Lung infiltrates treatment of
1074–1075, 1097–1102 elevated sedimentation rate and, 1247 diffuse alveolar hemorrhage,
changes in donor demographic and in renal failure, 1246 510t, 511f, 512
management, 1098 Lung Open Ventilation (LOV), 447 general measures, 512
indications and outcomes, 1097–1098, Lung point, 505, 506f specific interventions, 512
1097t, 1098ft Lung-protective strategies, do no harm, surgical versus medical management, 512
postoperative complications, 1100–1102, 445–447, 446t Massive hemothorax, 1156
1100t, 1101t Lung sliding, 505 Massively bleeding patient, 1156–1157
procedure, 1098–1099 Lung transplantation, 1090–1096 flail chest, 1157
Living will, 127 indications and outcomes, 1090–1092, pneumothorax and tracheobronchial injury,
LMA-ProSeal, 390 1090t, 1091ft, 1092ft 1156–1157
Loading dose, 1228 postoperative complications, 1093–1096, traumatic air embolism, 1157
Lobar torsion, 1073–1074 1094t, 1095t, 1096f Mast cell, 1272
Localized tetanus, 730 postoperative management, 1093, 1094t Maturity-onset diabetes of youth (MODY), 975
Logistic Organ Dysfunction System procedure, 1093 Mean arterial pressure, 242, 250
(LODS), 89 Lupus pneumonitis, systemic lupus Mean systemic pressure, 229f, 233
Logistic regression modeling, 84 erythematosus and, 1242 Measles virus, 674
Long QT syndrome (LQTS), 1324 LV/RV interdependence, 310 Mechanical ventilation, 377, 470
Long-term functional disability, 105, 106f Lymphadenopathy, 1290 liberation of patient from, 433

Index.indd 1346 23-01-2015 15:33:52